The invention offered for license is in the field of veterinary medicine. Specifically, it relates to a novel, serum-free medium used to isolate and expand MSCs.
MSCs are a potentially effective therapy for treating a variety of conditions in veterinary medicine. They are isolated and expanded in vitro in a medium that is supplemented with fetal bovine serum (FBS). However, the use of FBS as a medium component during manufacturing may pose several problems. FBS can be a source of unwanted pathogens. The serum can introduce carry-over components that may elicit an immune response. Further, lot-to-lot variations in FBS quality may introduce inconsistencies between batches of MSCs.
This invention uses a novel FBS-free medium that supports both the isolation and expansion of MSCs from canine adipose tissue while removing the unwanted pathogens, immune response and lot-to-lot variations.
|Potential Commercial Applications:||Competitive Advantages:|
|An isolation and expansion technique for manufacturing large quantities of MSCs in a FBS-free medium||The FBS-free medium removes the potential for adventitious pathogens, unwanted immune response and lot variations in MSCs during manufacture.
The MSCs cultivated in this novel medium exhibit a more uniform size and a shorter population doubling time as compared to the FBS medium.
Lax Devireddy (FDA)
Michael Myers (FDA)
Rudell Screven (FDA)
FDA Reference Number E-2017-010
Charlene Maddox, Ph.D.
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4232
Silver Spring, MD 20993